Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
Biogen's felzartamab wins first global approval in China for multiple myeloma
2+ day, 1+ hour ago (137+ words) TJ Biopharma led clinical development and the NMPA registration filing in Greater China. Under a deal struck in April 2026, Biogen acquired exclusive Greater China commercialization rights for felzartamab, consolidating global rights to the asset. Biogen will handle commercial launch; TJ…...
CSPC secures USD 30m from AstraZeneca for siRNA renal disease platform collaboration
2+ day, 3+ hour ago (76+ words) CSPC Pharmaceutical Group (HKEX: 01093) has received the USD 30 million upfront payment from AstraZeneca under their collaboration, option and license agreement for siRNA drug development targeting renal disease, confirming the deal signed in July 2026 has formally closed financially. Access the AllSci…...
Redx takes control of Skye in Nasdaq combination backed by USD 125m financing
1+ day, 22+ hour ago (89+ words) Concurrent financings are expected to provide approximately USD 125 million in aggregate gross proceeds, including a USD 68 million PIPE and USD 36 million Redx Series A financing. The combined company's cash is expected to fund operations into 2029 and through topline results from…...
Pfizer, Valneva Lyme vaccine enters EU review after Phase III
2+ day, 4+ hour ago (73+ words) Pfizer holds exclusive manufacturing and commercialization rights under a collaboration agreement with Valneva first signed in April 2020 and restructured in June 2022, under which Valneva is eligible to receive milestones and tiered royalties on net sales. Access the AllSci platform to…...
Atrium collects second USD 15m milestone from BMS as cardiovascular RNA programs advance
2+ day, 3+ hour ago (131+ words) The collaboration covers discovery, development, and commercialization of RNA-based therapies across multiple cardiovascular indications. Atrium is eligible for up to USD 1.35 billion in research and development milestone payments and up to USD 825 million in commercial milestones. BMS funds all clinical,…...
Zentalis adds USD 80.5m as azenosertib nears pivotal test
2+ day, 3+ hour ago (152+ words) The offering was priced on August 13, 2026, and is expected to close on August 17. Zentalis also granted underwriters a 30-day option to purchase up to an additional 3.45 million shares at the offering price. Meanwhile, the Phase III ASPENOVA confirmatory trial is…...
Khartis bags USD 95m for oral challenger to Tepezza
2+ day, 4+ hour ago (92+ words) Khartis was founded in 2024 by Robert Hoffman, who serves as CEO and Head of Drug Discovery; Craig Murphy, Chief Scientific Officer; and Chris LeMasters, Executive Chairman. All three previously worked together at XinThera, a small molecule drug discovery company acquired…...
Cancer's 'dark proteome' becomes new hunting ground for drug targets
2+ day, 21+ hour ago (122+ words) The USD 1.16 million OT2 award supports Dana-Farber as the US administrative home of the program. ILLUMINE will catalogue dark proteome entities across major cancer types, build a preclinical immunotherapy development pipeline around them, characterize their functions in cancer biology, and explore…...
IASO Bio acquires MediSix to expand CAR-T reach into T-cell malignancies
2+ day, 21+ hour ago (69+ words) Financial terms were not disclosed. The transaction is structured as a full acquisition, with MediSix operating as an integrated unit within IASO Bio following completion. No geographic restrictions on development rights were disclosed. Access the AllSci platform to explore the…...
ArriVent hands Allist Greater China rights to MUC16/NaPi2b ADC
2+ day, 21+ hour ago (91+ words) The deal covers mainland China, Hong Kong, Macau, and Taiwan. ArriVent retains all rights outside Greater China, including the FDA investigational new drug application cleared in May 2026. ArriVent has said first-in-human dosing was planned for the second half of 2026, making…...